CN105663111A - Application of Perovskone B to preparing of medicine for treating breast cancer - Google Patents
Application of Perovskone B to preparing of medicine for treating breast cancer Download PDFInfo
- Publication number
- CN105663111A CN105663111A CN201610084945.5A CN201610084945A CN105663111A CN 105663111 A CN105663111 A CN 105663111A CN 201610084945 A CN201610084945 A CN 201610084945A CN 105663111 A CN105663111 A CN 105663111A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- perovskoneb
- application
- perovskone
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of Perovskone B to preparing of medicine for treating breast cancer, and belongs to the technical field of new applications of medicine. According to the application, in-vitro MTT anti-tumor activity evaluation shows that the Perovskone B also has the remarkable inhibition effect on growth of human breast cancer cell strains 4T1, MCF-7, MDA-MB-231 and MCF-7B. In this way, the Perovskone B can be used for preparing the anti-breast-cancer medicine, and has the good development and application prospects. The application of the Perovskone B to preparing of the medicine for treating breast cancer is disclosed for the first time, and the Perovskone B has the quite high inhibition effect on the activity of breast cancer cells.
Description
Technical field
The present invention relates to the new application of compound PerovskoneB, particularly relate to PerovskoneB application in preparation treatment breast cancer medicines.
Background technology
Cancer is one of disease that human life's health hazard is maximum, has substantial amounts of people to die from cancer every year. The research and development of cancer therapy drug are always up the focus of study of pharmacy. Having 74% in antitumor drug is natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the antitumor drug that application effectiveness comparison is good clinically at present. Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound PerovskoneB that the present invention relates to is one and delivers (M.MoridiFarimani in 2011, etal., TriterpenoidswithRareCarbonSkeletonsfromSalviahydrangea: AntiprotozoalActivityandAbsoluteConfigurations.J.Nat.Pro d.2011, 74, 2200-2205.) noval chemical compound, this compound has brand-new framework types (M.MoridiFarimani, etal., TriterpenoidswithRareCarbonSkeletonsfromSalviahydrangea: AntiprotozoalActivityandAbsoluteConfigurations.J.Nat.Pro d.2011, 74, 2200-2205.), the PerovskoneB that the present invention relates to purposes treated in breast cancer medicines in preparation is belonged to first public, owing to belonging to brand-new structure type, and it is unexpectedly strong for the inhibitory activity of breast cancer cell, it is absent from being provided the possibility of any enlightenment by other compounds, possesses prominent substantive distinguishing features, the preventing and treating being simultaneously used for breast carcinoma obviously has significant progress.
Summary of the invention
It is an object of the invention to not find that it has the present situation of the report of anti-breast cancer activity according in existing PerovskoneB research, it is provided that PerovskoneB application in preparing anti-breast cancer medicines.
Described compound PerovskoneB, structure is such as shown in formula I:
Described PerovskoneB application in preparation treatment breast cancer medicines, breast cancer cell is Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B.
One treats breast cancer medicines, PerovskoneB be that active component interpolation adjuvant is prepared from, and preparation method, for taking 5 g of compound PerovskoneB, adds 195 grams of dextrin, and mixing, Conventional compression makes 1000.
One treats breast cancer medicines, PerovskoneB be that active component adds adjuvant and is prepared from, and preparation method, for taking 5 g of compound PerovskoneB, adds starch 195 grams, mixes, encapsulated makes 1000.
The present invention is found by external MTT antineoplastic activity evaluation, PerovskoneB to Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B growth also there is significant inhibitory action, it is suppressed that the IC50 value of this 4 strain Growth of Cells respectively 1.89 ± 0.48 μMs, 2.49 ± 0.76 μMs, 2.74 ± 0.35 μMs and 1.98 ± 0.54 μMs. Therefore, PerovskoneB can be used for preparing anti-breast cancer medicines, has good development prospect.
The PerovskoneB that the present invention relates to purposes treated in breast cancer medicines in preparation is belonged to first public, owing to framework types belongs to brand-new framework types, and it is unexpectedly strong for the inhibitory activity of breast cancer cell, it is absent from being provided the possibility of any enlightenment by other compounds, possessing prominent substantive distinguishing features, the preventing and treating being simultaneously used for breast carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but is defined in the claims.
Detailed description of the invention
The preparation method of compound PerovskoneB involved in the present invention is referring to document (M.MoridiFarimani, etal., TriterpenoidswithRareCarbonSkeletonsfromSalviahydrangea: AntiprotozoalActivityandAbsoluteConfigurations.J.Nat.Pro d.2011,74,2200-2205.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but is defined in the claims.
Embodiment 1: the preparation of compound PerovskoneB tablet involved in the present invention:
Taking 20 g of compound PerovskoneB, the customary adjuvant 180 grams of tablet is prepared in addition, and mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound PerovskoneB capsule involved in the present invention:
Taking 20 g of compound PerovskoneB, customary adjuvant such as starch 180 grams of capsule are prepared in addition, mixing, encapsulated make 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay to evaluate the compound PerovskoneB growth inhibited effect to Breast cancer lines
1. method: be in the cell of growth logarithmic (log) phase: Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B (buying from Chinese Academy of Sciences's cell bank) are with 1.5 × 104Concentration kind is in 96 orifice plates. Original culture medium is sucked after cell cultivation 24h is adherent. Test is divided into blank group, drug treating group. Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the PerovskoneB of 0.01 μM and 0.001 μM. After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO2Incubator cultivates 4h, 100 μ L of supernatant are sucked then along culture fluid top, add 100 μ LDMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, each process sets 6 repeating holes. Cell survival rate (%)=Δ OD drug treating/Δ OD blank × 100.
2. result: PerovskoneB to Breast cancer lines P4T1, MCF-7, MDA-MB-231 and MCF-7B growth there is significant inhibitory action.This compound suppresses the IC50 value respectively 1.89 ± 0.48 μMs, 2.49 ± 0.76 μMs, 2.74 ± 0.35 μMs and 1.98 ± 0.54 μMs of Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B growth.
Shown by above-described embodiment, the PerovskoneB of the present invention to Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B growth there is good inhibiting effect. Thus proving, the PerovskoneB of the present invention has anti-breast cancer activity, can be used for preparing anti-breast cancer medicines.
Claims (4)
1.PerovskoneB application in treatment breast cancer medicines, described compound PerovskoneB structure is such as shown in formula I:
Formula I.
2. PerovskoneB application in treatment breast cancer medicines as claimed in claim 1, it is characterised in that breast cancer cell is Breast cancer lines 4T1, MCF-7, MDA-MB-231 and MCF-7B.
3. a treatment breast cancer medicines, it is characterised in that PerovskoneB described in claim 1 is that active component interpolation adjuvant is prepared from, and preparation method, for taking 5 g of compound PerovskoneB, adds 195 grams of dextrin, and mixing, Conventional compression makes 1000.
4. a treatment breast cancer medicines, it is characterised in that PerovskoneB described in claim 1 is that active component adds adjuvant and is prepared from, and preparation method, for taking 5 g of compound PerovskoneB, adds starch 195 grams, mixes, encapsulated makes 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610084945.5A CN105663111A (en) | 2016-02-14 | 2016-02-14 | Application of Perovskone B to preparing of medicine for treating breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610084945.5A CN105663111A (en) | 2016-02-14 | 2016-02-14 | Application of Perovskone B to preparing of medicine for treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105663111A true CN105663111A (en) | 2016-06-15 |
Family
ID=56304173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610084945.5A Pending CN105663111A (en) | 2016-02-14 | 2016-02-14 | Application of Perovskone B to preparing of medicine for treating breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105663111A (en) |
-
2016
- 2016-02-14 CN CN201610084945.5A patent/CN105663111A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| M. MORIDI FARIMANI ET AL.: "Triterpenoids with Rare Carbon Skeletons from Salvia hydrangea:Antiprotozoal Activity and Absolute Configurations", 《J. NAT. PROD.》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250250A (en) | Application of Nootkatone in preparation of medicine for treating nasopharyngeal carcinoma | |
| CN103251609A (en) | Application of Aspeverin in preparation of medicines for treating tongue cancer | |
| CN105456243A (en) | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer | |
| CN105663111A (en) | Application of Perovskone B to preparing of medicine for treating breast cancer | |
| CN105267221A (en) | Application of Norzoanthamine in preparation of drugs for treating prostate cancer | |
| CN105311026A (en) | Application of Leuconoxine in preparation of medicines for treating pancreatic cancer | |
| CN106309441A (en) | Application of Fistulains A in preparation of drugs for treating cervical cancer | |
| CN105267193A (en) | Application of Periconianone B to preparation of medicine for treating ovarian cancer | |
| CN105669822A (en) | Application of Epishionol to preparing of medicine for treating breast cancer | |
| CN105663121A (en) | Application of Aogacillin B in preparation of breast cancer treatment drug | |
| CN103479630B (en) | The application of Lycojaponicumin A in preparation treatment breast cancer medicines | |
| CN103462969B (en) | The application of Incarviatone A in preparation treatment breast cancer medicines | |
| CN103446147B (en) | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine | |
| CN103463052B (en) | The application of Lycojaponicumin A in preparation treatment cervical cancer medicine | |
| CN103405418A (en) | Application of Chukrasone B in medicine for treating breast cancer | |
| CN105496990A (en) | Application of Heyneanones A to preparation of drugs for treating breast cancer | |
| CN105497016A (en) | Application of Penicillactones A to preparation of drug for treating breast cancer | |
| CN105456262A (en) | Application of Melodinine E in preparing medicine for treating endometrial cancer | |
| CN105456259A (en) | Application of Penibruguieramine A in preparing medicine for treating bladder cancer | |
| CN105496989A (en) | Application of Heyneanones A to preparation of drug for treating laryngeal cancer | |
| CN105287492A (en) | Application of Mollanol A in preparation of medicines for treating cervical carcinoma | |
| CN105232534A (en) | Application of Daphnilongeranin B in preparing drugs for treating ileocecum cancer | |
| CN105412070A (en) | Application of Salvadione C in preparation of rectal cancer treatment drug | |
| CN105726547A (en) | Application of Flabelliferin B to preparation of medicine for treating breast cancer | |
| CN105362260A (en) | Application of Spirooliganone B in preparing medicine for treating tongue cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |
|
| RJ01 | Rejection of invention patent application after publication |